Rivaroxaban (Xarelto,Bay 59-7939)

DRUG2 trials

Sponsors

Bayer

Conditions

Coronary Artery Disease (CAD)Non-valvular Atrial Fibrillation (NVAF)Prevention of Atherothrombotic EventsSymptomatic Peripheral Artery Disease (Symptomatic PAD)

Unknown Phase

A Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF)

CompletedNCT03887780

BayerNon-valvular Atrial Fibrillation (NVAF)

Start: 2019-10-03End: 2024-12-16Updated: 2025-01-08

Study to Learn More About the Safety and Effectiveness of Rivaroxaban (Xarelto) When Given Together With Acetylsalicylic Acid to Indian People With Narrowing of the Arteries of the Heart (CAD) and/or With Reduced Blood Flow in the Arteries of the Legs and Arms With Symptoms (Symptomatic PAD)

CompletedNCT04298567

BayerCoronary Artery Disease (CAD), Prevention of Atherothrombotic Events, Symptomatic Peripheral Artery Disease (Symptomatic PAD)

Start: 2022-02-25End: 2024-06-06Updated: 2024-06-28